MSME (Udyam registered) Ministry of MSME
- Udyam number
- UDYAM-HR-03-0064394
Torrvis Pharmaceuticals Private Limited
Torrvis Pharmaceuticals Private Limited - pharma in Delhi, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹31.91 Cr
▲ 12% YoY
Net profit · FY 2025
₹25.91 Lakh
Net margin 0.8%
EBITDA · FY 2025
₹1.37 Cr
EBITDA margin 4.3%
Authorised capital
₹1 Lakh
Registered with MCA
Paid-up capital
₹1 Lakh
Issued & subscribed
Open charges
₹2.1 Cr
Secured borrowings
Company age
6 yrs
Est. 2020
Directors on board
2
As per MCA filings
About Torrvis Pharmaceuticals Private Limited
Data last updated:
Torrvis Pharmaceuticals Private Limited is a private limited company based in Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 11 December 2020 and has been in existence for over 6 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24233DL2020PTC374452. Its GSTIN is 06AAICT2918D1ZI (Haryana).
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Sanjay Gupta and Meenakshi Gupta.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Flat No.302 Narmada Blk N – 5 Sec – D Pkt – 6 Vasant Kunj, Delhi, India – 110070.
As per the financials filed for FY 2025, the company reported a revenue of ₹31.91 Cr, a growth of 12% compared to the previous year. For the same year it recorded a net profit of ₹25.91 Lakh (net margin 0.8%) and EBITDA of ₹1.37 Cr (EBITDA margin 4.3%). Revenue has grown at a compounded annual rate (CAGR) of 224% over three years.
As per MCA filings, the company has open charges of ₹2.1 Cr on record. Court records list 4 cases involving the company, including 4 filed by the company; 2 cases are pending.
Torrvis Pharmaceuticals Private Limited is registered as an MSME under the Udyam registration framework (Reg. No. UDYAM-HR-03-0064394).
Company details
CIN U24233DL2020PTC374452
Registration Number 374452
Incorporation Date 11 December 2020
ROC Delhi
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
MSME Classification MSME
Udyam Registration UDYAM-HR-03-0064394
Key People
Sanjay Gupta Director Meenakshi Gupta Director Recognitions & Rankings of Torrvis Pharmaceuticals
Contact details
Torrvis Pharmaceuticals Private Limited's registered office is in Delhi, Delhi. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressFlat No.302 Narmada Blk N – 5 Sec – D Pkt – 6 Vasant Kunj, Delhi, India – 110070
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Torrvis Pharmaceuticals Private Limited, buy the company report.
Comprehensive company report
Torrvis Pharmaceuticals Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Business activity
The main business activity of Torrvis Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Torrvis Pharmaceuticals Private Limited, buy the company report.
Financials of Torrvis Pharmaceuticals Private Limited
FY 2025 filings availableTorrvis Pharmaceuticals Private Limited reported revenue of ₹31.91 Cr (up 12% YoY) for FY 2025.
Revenue · FY 2025
₹31.91 Cr ▲ 12%
Net profit · FY 2025
₹25.91 Lakh margin 0.8%
EBITDA · FY 2025
₹1.37 Cr margin 4.3%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 12%
3 years · compounded
▲ 224%
EBITDA CAGR growth
3 years · compounded
▲ 208%
Revenue has grown at a compounded annual rate (CAGR) of 224% over three years, including 12% growth in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹1.37 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹25.91 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 4.3% | ||||
| Net Profit Margin | 0.8% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Torrvis Pharmaceuticals Private Limited, buy the company report.
Board of directors of Torrvis Pharmaceuticals Private Limited
Torrvis Pharmaceuticals has 2 directors on record. No former directors are listed.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sanjay Gupta Also directs: MKS Healthcare Private Limited, Cosmax Pharma Private Limited, Skymap Packaging Private Limited and 5 more | Director | 11 Dec 2020 | 5 Years 10 Months | Current |
| Meenakshi Gupta Also directs: MKS Healthcare Private Limited, Skymap Packaging Private Limited, Organic Secrets Private Limited and 5 more | Director | 11 Dec 2020 | 5 Years 10 Months | Current |
Peer comparison
Torrvis Pharmaceuticals Private Limited is compared with the 6 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Sangrose Laboratories Private Limited | ₹32.28 Cr (FY 2024) | 34.0% | Alappuzha, Kerala, India | |||
| Adora Products Private Limited | ₹32.02 Cr (FY 2024) | 43.0% | Aurangabad, Maharashtra, India | |||
| Dano Vaccines and Biologicals Pvt Ltd | ₹31.96 Cr (FY 2025) | 3.0% | Hyderabad.Andhra Pradesh, Telangana, India | |||
| Torrvis Pharmaceuticals Private Limitedthis company | ₹31.91 Cr (FY 2025) | ₹25.91 Lakh | 0.8% | 12.0% | Delhi, India | |
| R P L (India) Pharmaceuticals Private Limited | ₹31.91 Cr (FY 2025) | 13.0% | New Delhi, Delhi, India | |||
| Aan Lifescience Private Limited | ₹31.79 Cr (FY 2025) | -1.0% | Mahemdavad, Gujarat, India | |||
| Total Drugs and Intermediates Private Limited | ₹31.73 Cr (FY 2025) | 48.0% | Hyderabad, Telangana, India |
To see the full peer comparison of Torrvis Pharmaceuticals Private Limited, buy the company report.
Auditor
Torrvis Pharmaceuticals Private Limited is audited by Singla Tayal & Co. for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Singla Tayal & Co. | FY 2023 | 000882N |
Shareholding
The shareholding of Torrvis Pharmaceuticals Private Limited is on record for 3 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|
| Promoters | |||
| Domestic institutional investors (DII) | |||
| Foreign institutional investors (FII) | |||
| Public | |||
| Others |
To see the full shareholding pattern of Torrvis Pharmaceuticals Private Limited, buy the company report.
Charges & borrowings
Open charges
₹2.1 Cr
Satisfied charges
None
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 18 Sep 2023 | 100826078 | Hdfc Bank Limited | ₹2.1 Cr | Open |
Total charge records: 1 View all charges
Legal cases
Torrvis Pharmaceuticals Private Limited has 4 court cases on record: 4 filed by Torrvis Pharmaceuticals. 2 cases are pending and 2 are disposed.
Total cases
4
Filed by the company
4
Pending
2
Disposed
2
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 4 | 0 | 2 |
Cases on record (4 of 4)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Faridabad, Haryana | Cheque dishonour complaint | Filed by the company against M/S Geeta Devi Distributors | Pending |
| District court, Faridabad, Haryana | Cheque dishonour complaint | Filed by the company against M/S Krishna Medical Hall and 1 other | Pending |
| District court, Faridabad, Haryana | Cheque dishonour complaint | Filed by the company against M/S Tarak Pharma and 1 other | Disposed |
| District court, Faridabad, Haryana | Cheque dishonour complaint | Filed by the company against Ms/ Shri Maruti Pharma | Disposed |
To see the full case history of Torrvis Pharmaceuticals Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Torrvis Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Torrvis Pharmaceuticals Private Limited has 1 active EPFO establishment as of Apr 08, 2024.
Active EPFO establishments
1
GST
Torrvis Pharmaceuticals has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 06AAICT2918D1ZI | Haryana | Active | 02 Feb 2021 |
To see the full GST registrations and return filing status of Torrvis Pharmaceuticals Private Limited, buy the company report.
Recent activity
Torrvis Pharmaceuticals Private Limited has 2 board changes on record since 2020: 2 appointments. The latest: Meenakshi Gupta was appointed as Director on 11 Dec 2020.
AGM
Torrvis Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Filing
Torrvis Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Delhi I.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 210.00 Lakh with Charge ID 100826078 was registered on 18 Sep 2023.
Appointed
Meenakshi Gupta was appointed as Director.
Appointed
Sanjay Gupta was appointed as Director.
Incorporation
11 Dec 2020
Torrvis Pharmaceuticals Private Limited was registered on 11 Dec 2020 with Roc Delhi I & aged 5 years 10 months as per MCA records.
Frequently asked questions
Torrvis Pharmaceuticals is an active private limited company based in Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 11 December 2020 (6+ years old) and is registered under CIN U24233DL2020PTC374452.
Torrvis Pharmaceuticals has 2 current directors:
- Sanjay Gupta - Director
- Meenakshi Gupta - Director
The latest financial statements of Torrvis Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2021 are in the company report.
The GSTIN of Torrvis Pharmaceuticals is 06AAICT2918D1ZI, registered in Haryana.
The CIN (Corporate Identification Number) of Torrvis Pharmaceuticals is U24233DL2020PTC374452. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Torrvis Pharmaceuticals has 4 court cases on record: 4 filed by the company. 2 are pending.
Torrvis Pharmaceuticals was incorporated on 11 December 2020, making it 6+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of Torrvis Pharmaceuticals by revenue are Sangrose Laboratories Private Limited, Adora Products Private Limited, Dano Vaccines and Biologicals Pvt Ltd, R P L (India) Pharmaceuticals Private Limited, Aan Lifescience Private Limited and 1 more, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Meenakshi Gupta was appointed as Director on 11 Dec 2020. Sanjay Gupta was appointed as Director on 11 Dec 2020.
Yes, Torrvis Pharmaceuticals is registered as an MSME under Udyam registration (number: UDYAM-HR-03-0064394).
The registered office of Torrvis Pharmaceuticals is at Flat No.302 Narmada Blk N – 5 Sec – D Pkt – 6 Vasant Kunj, Delhi, India – 110070.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages